BLUEJAY DIAGNOSTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.75 USD | -20.29% |
|
-6.28% | -71.82% |
| 05-31 | Bluejay Diagnostics, Inc. announced a financing transaction | CI |
| 05-15 | Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 49.92 | 7.656 | 1.512 |
| Enterprise Value (EV) 1 | 30.88 | -1.946 | -0.3267 |
| P/E ratio | -6.25 x | -0.82 x | -0.13 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | 30,741,431 x | - |
| EV / Revenue | - | -7,813,576 x | - |
| EV / EBITDA | -10 x | 0.21 x | 0.03 x |
| EV / FCF | -8,604,756 x | 352,856 x | 60,713 x |
| FCF Yield | -0% | 0% | 0% |
| Price to Book | 2.53 x | 0.67 x | 0.52 x |
| Nbr of stocks (in thousands) | 122 | 126 | 155 |
| Reference price 2 | 409.6 | 60.78 | 9.760 |
| Announcement Date | 10/03/22 | 20/03/23 | 28/03/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales | - | - | - | 0.249 | - |
| EBITDA 1 | -1.488 | -1.039 | -3.084 | -9.161 | -9.663 |
| EBIT 1 | -1.631 | -1.196 | -3.23 | -9.318 | -10.31 |
| Operating Margin | - | - | - | -3,741.48% | - |
| Earnings before Tax (EBT) 1 | -0.8198 | -1.158 | -3.488 | -9.297 | -9.954 |
| Net income 1 | -0.8198 | -1.158 | -3.488 | -9.297 | -9.954 |
| Net margin | - | - | - | -3,733.11% | - |
| EPS 2 | -41.68 | -58.89 | -65.49 | -73.77 | -72.62 |
| Free Cash Flow | - | -0.1367 | -3.588 | -5.515 | -5.381 |
| FCF margin | - | - | - | -2,214.38% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 22/07/21 | 22/07/21 | 10/03/22 | 20/03/23 | 28/03/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|
| Net sales 1 | - | - | - |
| EBITDA | - | - | - |
| EBIT 1 | -2.904 | -2.341 | -2.387 |
| Operating Margin | - | - | - |
| Earnings before Tax (EBT) 1 | -2.813 | -2.298 | -2.303 |
| Net income 1 | -2.813 | -2.298 | -2.303 |
| Net margin | - | - | - |
| EPS 2 | -22.00 | -16.64 | -14.24 |
| Dividend per Share | - | - | - |
| Announcement Date | 14/08/23 | 09/11/23 | 28/03/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | 0.97 | 0.14 | - | - | - |
| Net Cash position 1 | - | - | 19 | 9.6 | 1.84 |
| Leverage (Debt/EBITDA) | -0.6539 x | -0.1381 x | - | - | - |
| Free Cash Flow | - | -0.14 | -3.59 | -5.51 | -5.38 |
| ROE (net income / shareholders' equity) | - | 292% | -34.8% | -58.2% | -138% |
| ROA (Net income/ Total Assets) | - | -61.4% | -17.9% | -33.7% | -70.1% |
| Assets 1 | - | 1.885 | 19.47 | 27.57 | 14.2 |
| Book Value Per Share 2 | -149.0 | -214.0 | 162.0 | 91.30 | 18.70 |
| Cash Flow per Share 2 | 4.880 | 46.40 | 152.0 | 80.10 | 14.30 |
| Capex 1 | 0.01 | - | 0.02 | 1.2 | 0.7 |
| Capex / Sales | - | - | - | 481.56% | - |
| Announcement Date | 22/07/21 | 22/07/21 | 10/03/22 | 20/03/23 | 28/03/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -71.82% | 998K | |
| -44.08% | 7.63B | |
| +8.98% | 3.61B | |
| +3.94% | 2.36B | |
| -24.94% | 1.86B | |
| -17.38% | 1.74B | |
| +4.89% | 913M | |
| +21.75% | 763M | |
| -11.57% | 678M | |
| -30.82% | 500M |
- Stock Market
- Equities
- BJDX Stock
- Financials Bluejay Diagnostics, Inc.
